ViaLase shares updates on new technology to treat glaucoma, company updates and upcoming trials

Conferences|ASCRS

Tom Frinzi, executive chairman of ViaLase, a new company based in Orange County, gives an update on the company, sharing some exciting new things happening.

Related Videos
Related Content

BLOG: MicroPulse TLT provides a lifestyle-friendly option

June 9th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

VVN539 meets primary study endpoints in US phase IIa clinical study

June 5th 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

AI used to advance drug delivery system for glaucoma and other chronic diseases

May 25th 2023

BLOG: MicroPulse TLT provides a lifestyle-friendly option

June 9th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

VVN539 meets primary study endpoints in US phase IIa clinical study

June 5th 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

AI used to advance drug delivery system for glaucoma and other chronic diseases

May 25th 2023

BLOG: MicroPulse TLT provides a lifestyle-friendly option

June 9th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

VVN539 meets primary study endpoints in US phase IIa clinical study

June 5th 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

AI used to advance drug delivery system for glaucoma and other chronic diseases

May 25th 2023
© 2023 MJH Life Sciences

All rights reserved.